Rhabdomyosarcoma
Conditions
Keywords
Rhabdomyosarcoma, Radiation therapy, Proton beam
Brief summary
This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy. PRIMARY OBJECTIVE: * Estimate event-free survival for intermediate risk participants treated with vincristine, dactinomycin and cyclophosphamide with the addition of maintenance anti-angiogenic therapy. SECONDARY OBJECTIVES: * Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection. * Maintain a high local control rate in participants treated with surgery and/or limited volume proton and photon radiation without dose escalation. * Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume. * Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic chemotherapy in intermediate and high risk patients following standard chemotherapy. * Estimate the event free survival for high risk patients receiving interval dose compressed therapy and maintenance anti-angiogenic therapy. * Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.
Detailed description
Participants will be stratified based on both a pretreatment staging system and a post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1) participants will consist of chemotherapy and radiation. Low-risk (subset 2) and intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation therapy. High-risk participants will also receive additional maintenance therapy with anti-angiogenic chemotherapy.
Interventions
DRUGVincristine
Dosage and route of administration: * \< 1 year of age=0.025 mg/kg intravenously (IV) * \> 1 year and \< 3 years= 0.05 mg/kg IV * ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.
DRUGDactinomycin
Dosage and route of administration: * \< 1 year=0.025 mg/kg IV push * ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.
DRUGCyclophosphamide
Dosage and route of administration: During VAC chemotherapy: * \< 3 years of age = 40 mg/kg IV * ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA. During maintenance for intermediate-risk participants: * oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)
PROCEDURESurgical Resection
Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
PROCEDURERadiation
Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
DRUGBevacizumab
Dosage and route of administration: 15 mg/kg/dose/day IV.
DRUGSorafenib
Dosage and route of administration: 90 mg/m\^2/dose twice daily.
If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice. High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.
PROCEDURELymph Node Sampling
Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.
DRUGIrinotecan
Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
DRUGIfosfamide
Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
DRUGEtoposide
Dosage and Route of Administration: Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis
DRUGEtoposide Phosphate
Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
DRUGDoxorubicin
Dosage and route of Administration: Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.
DRUGDexrazoxane
Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin. Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.
DRUG^1^1C-methionine
Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Sponsors
St. Jude Children's Research Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed participants with localized rhabdomyosarcoma (RMS). * Must have either low-, intermediate-, or high-risk disease, defined as: * Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II) * Intermediate-risk: Embryonal, botryoid, or spindle cell RMS Stage 2 or 3 and Group III; Alveolar, undifferentiated, or anaplastic RMS: Stage 1-3, group I-I; I) * High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4). * Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol. * Age \< 22 years (eligible until 22nd birthday) * Performance level corresponding to ECOG score of 0, 1, or 2. The Lansky performance score should be used for participants \< 16 years * Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment. Prior biopsy, surgical resection and lymph node sampling is allowed. * Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection. * Adequate bone marrow function defined as: * Peripheral absolute neutrophil count (ANC) ≥ 750/μL * Platelet count ≥ 75,000/μL (transfusion independent) * Adequate liver function defined as total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age. Participants with biliary or hepatic primaries with bilirubin values greater than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met. * Adequate renal function defined as: * Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.732 or * Serum creatinine based on age and gender * Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract. * Patients requiring emergency radiation therapy are eligible for enrollment on this study. * Females of child-bearing potential cannot be pregnant or breast-feeding. Female participants ≥ 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment. Female participants who are breast feeding must agree to stop breast feeding. * Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed. * No evidence of active, uncontrolled infection. * All participants and/or their parents or legal guardians must sign a written informed consent.
Exclusion criteria
* Participants who fail to meet one or more of the inclusion criteria will be excluded. Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study: * Newly diagnosis or suspected diagnosis of previously untreated participants with rhabdomyosarcoma (RMS). NOTE: Patients with suspected diagnosis of RMS may enroll on screening part of study but must have histologic diagnosis to enroll on treatment part of study. * Must have either intermediate-risk or high risk disease. * 0-21 years of age.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (intermediate risk arm) | 2 years after last intermediate risk arm enrollment | To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms) | 2 years after last low or intermediate arm enrollment | Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection. |
| Rate of false negative and false positive the sentinel lymph node procedure (high risk arm) | 5 years after last high risk arm enrollment | Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection. |
| Local failure rate (low and intermediate risk arms) | 2 years after last low or intermediate risk arm enrollment | Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation |
| Local failure rate (high risk arm) | 5 years after last high risk arm enrollment | Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation |
| Event-free survival (high risk arm) | 5 years after last high-risk arm enrollment | To estimate event-free survival for high risk participants. |
| Patterns of failure (high risk arm) | 5 years after last high risk arm enrollment | Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume |
| Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm) | 2 years after last low or intermediate risk arm enrollment | Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy. |
| Number of patients that complete all cycles of maintenance chemotherapy (high risk arm) | 5 years after last high risk arm enrollment | Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy. |
| Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms) | 2 years after last enrollment | Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy. |
| Patterns of failure (low and intermediate risk arms) | 2 years after last low or intermediate risk arm enrollment | Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume |
Countries
United States
Outcome results
None listed